BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23200173)

  • 1. Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer.
    Kelly P; Das P; Pinnix CC; Beddar S; Briere T; Pham M; Krishnan S; Delclos ME; Crane CH
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e143-9. PubMed ID: 23200173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of dosimetric parameters associated with acute gastrointestinal toxicity and upper gastrointestinal bleeding in locally advanced pancreatic cancer patients treated with gemcitabine-based concurrent chemoradiotherapy.
    Nakamura A; Shibuya K; Matsuo Y; Nakamura M; Shiinoki T; Mizowaki T; Hiraoka M
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):369-75. PubMed ID: 22381898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma.
    Huang J; Robertson JM; Ye H; Margolis J; Nadeau L; Yan D
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1120-5. PubMed ID: 22099048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the para-aortic nodes in gynecologic cancer.
    Verma J; Sulman EP; Jhingran A; Tucker SL; Rauch GM; Eifel PJ; Klopp AH
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):357-62. PubMed ID: 24411609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose escalation of radiation therapy with or without induction chemotherapy for unresectable locally advanced pancreatic cancer.
    Ma SJ; Prezzano KM; Hermann GM; Singh AK
    Radiat Oncol; 2018 Nov; 13(1):214. PubMed ID: 30400962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients.
    Mattiucci GC; Boldrini L; Nardangeli A; D'Aviero A; Buwenge M; Cellini F; Deodato F; Dinapoli N; Frascino V; Macchia G; Morganti AG; Valentini V
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):661-667. PubMed ID: 33001271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation.
    Krishnan S; Chadha AS; Suh Y; Chen HC; Rao A; Das P; Minsky BD; Mahmood U; Delclos ME; Sawakuchi GO; Beddar S; Katz MH; Fleming JB; Javle MM; Varadhachary GR; Wolff RA; Crane CH
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):755-65. PubMed ID: 26972648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum.
    Coia L; Hoffman J; Scher R; Weese J; Solin L; Weiner L; Eisenberg B; Paul A; Hanks G
    Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):161-7. PubMed ID: 8083109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
    Crane CH; Abbruzzese JL; Evans DB; Wolff RA; Ballo MT; Delclos M; Milas L; Mason K; Charnsangavej C; Pisters PW; Lee JE; Lenzi R; Vauthey JN; Wong AB; Phan T; Nguyen Q; Janjan NA
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1293-302. PubMed ID: 11955742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients.
    Zschaeck S; Blümke B; Wust P; Kaul D; Bahra M; Riess H; Klein F; Sinn M; Pelzer U; Budach V; Ghadjar P
    PLoS One; 2017; 12(10):e0186341. PubMed ID: 29023527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duodenal and other gastrointestinal toxicity in cervical and endometrial cancer treated with extended-field intensity modulated radiation therapy to paraaortic lymph nodes.
    Poorvu PD; Sadow CA; Townamchai K; Damato AL; Viswanathan AN
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1262-8. PubMed ID: 23182395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer.
    Hunter KU; Feng FY; Griffith KA; Francis IR; Lawrence TS; Desai S; Murphy JD; Zalupski MM; Ben-Josef E
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):921-6. PubMed ID: 22208966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
    Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
    Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer.
    Shen ZT; Zhou H; Li AM; Ji XQ; Jiang CC; Yuan X; Li B; Zhu XX; Huang GC
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):417-428. PubMed ID: 31667573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis.
    Tchelebi LT; Lehrer EJ; Trifiletti DM; Sharma NK; Gusani NJ; Crane CH; Zaorsky NG
    Cancer; 2020 May; 126(10):2120-2131. PubMed ID: 32125712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-fluorouracil-based chemoradiation in unresectable pancreatic carcinoma: Phase I-II dose-escalation study.
    Morganti AG; Valentini V; Macchia G; Mattiucci GC; Costamagna G; Deodato F; Smaniotto D; Luzi S; Balducci M; Barbi S; Perri V; Trodella L; Cellini N
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1454-60. PubMed ID: 15275732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
    Park JJ; Hajj C; Reyngold M; Shi W; Zhang Z; Cuaron JJ; Crane CH; O'Reilly EM; Lowery MA; Yu KH; Goodman KA; Wu AJ
    Acta Oncol; 2017 Dec; 56(12):1746-1753. PubMed ID: 28661823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
    Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy.
    Singh AK; Lockett MA; Bradley JD
    Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):337-41. PubMed ID: 12527046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer.
    Holyoake DLP; Warren DR; Hurt C; Aznar M; Partridge M; Mukherjee S; Hawkins MA
    Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):418-426. PubMed ID: 29602584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.